Five computational developability guidelines for therapeutic antibody profiling
Therapeutic mAbs must not only bind to their target but must also be free from “developability issues” such as poor stability or high levels of aggregation. While small-molecule drug discovery benefits from Lipinski’s rule of five to guide the selection of molecules with appropriate biophysical properties, there is currently no in silico analog for antibody design. Here, we model the variable domain structures of a large set of post-phase-I clinical-stage antibody therapeutics (CSTs) and calc...Expand abstract
- Publication status:
- Peer review status:
- Peer reviewed
- Publisher's version
- Publisher copy:
- National Academy of Sciences Publisher's website
- Proceedings of the National Academy of Sciences Journal website
- Publication date:
- Acceptance date:
- Pubs id:
- Local pid:
- Copyright holder:
- Raybould et al.
- Copyright date:
Copyright © 2019 the Authors. Published by PNAS.
This open access article is distributed under Creative Commons Attribution License 4.0 (CC BY).